FDA approves Brineura for type of Batten disease – Healio

FDA approves Brineura for type of Batten disease
Healio
The FDA has approved cerliponase alfa to curb the loss of ambulation among patients aged 3 years and older diagnosed with late infantile neuronal ceroid lipofuscinosis type 2, an extremely rare and fatal autosomal recessive neurodegenerative disorder, …
FDA action buoys Memphis family battling brain diseaseThe Commercial Appeal
BioMarin’s Brineura Gets FDA Approval As First Treatment For Type Of Batten DiseaseTech Times
Brineura Approved for Rare Genetic Illness Affecting KidsArizona Daily Star
PerfScience –Pulse Headlines –FDA.gov –AOL
all 53 news articles »